Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177138 · ClinicalTrials.gov registry record · Phase 4
Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
A Phase 4 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT00177138 is a Phase 4 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 9 participants.
The verdict
NCT00177138, a Phase 4 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1) immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin, tacrolimus, and MMF (Group 2). This study will investigate the first protocol that is both steroid-free and calcineurin inhibitor-free in pancreas after kidney transplant recipients.
Interventions
- DRUG Alemtuzumab
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177138
The ClinicalTrials.gov registry entry for NCT00177138 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alemtuzumab is the first listed.
NCT00177138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177138 about?
NCT00177138 is a clinical study titled "Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation". This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Gr...
What is the current status of trial NCT00177138?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2004-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00177138?
The interventions under investigation include: Alemtuzumab (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00177138?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.